Fig. 2From: Dose selection for glycopyrrolate/eFlow® phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studiesGOLDEN 6 study design. aSafety follow-up was conducted 5–7 days after the Early Termination visit for subjects who discontinued the study prior to completing all scheduled treatment periods. BID, twice dailyBack to article page